Related Experiment Video

Updated: May 12, 2026

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration
08:55

A Novel In Vitro Wound Healing Assay to Evaluate Cell Migration

Published on: March 17, 2018

PKG II inhibits EGF/EGFR-induced migration of gastric cancer cells

Lu Jiang1, Ting Lan, Yongchang Chen

  • 1Department of Physiology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.

Plos One
|April 25, 2013
PubMed
Abstract

Insights

Type II cGMP dependent protein kinase (PKG II) inhibits gastric cancer cell migration by blocking epidermal growth factor receptor (EGFR) activation. This PKG II action disrupts key signaling pathways, offering a potential therapeutic target for gastric cancer.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Previous studies indicated Type II cGMP dependent protein kinase (PKG II) inhibits gastric cancer cell proliferation by blocking epidermal growth factor receptor (EGFR) and MAPK/ERK signaling.
  • This suggests PKG II may also inhibit other EGFR-triggered pathways and gastric cancer cell activities.

Purpose of the Study:

  • To investigate the inhibitory effect of PKG II on epidermal growth factor (EGF)/EGFR-induced migration in gastric cancer cells.
  • To identify the related signal transduction pathways involved in this inhibition.

Main Methods:

  • Gastric cancer cell line (AGS) was infected with Ad-PKG II and treated with 8-pCPT-cGMP to increase PKG II expression and activity.
  • Western Blotting and "Pull-down" assays were used to detect protein phosphorylation and small G protein activity (Ras, Rac1).
  • Cell migration was assessed using trans-well assays, and PKG II binding to EGFR was confirmed by Co-IP.

Main Results:

  • EGF stimulation increased AGS cell migration, involving PLCγ1 and ERK signaling pathways.
  • PKG II significantly inhibited EGF-induced migration and blocked EGF-initiated PLCγ1 and MAPK/ERK signaling.
  • This inhibition occurred by preventing EGF-induced phosphorylation of EGFR at Tyr 992 and Tyr 1068, with PKG II binding to EGFR and causing threonine phosphorylation.

Conclusions:

  • PKG II effectively inhibits EGF-induced migration and related PLCγ1 and MAPK/ERK signaling in gastric cancer cells.
  • PKG II exerts broad inhibition on EGF/EGFR signaling and biological activities.
  • PKG II phosphorylates EGFR, blocking its activation and thereby inhibiting gastric cancer cell migration.

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...